EDITORIAL | | WORLD SYMPOSIUM ON PULMONARY HYPERTENSION An overview of the 6th World Symposium on Pulmonary Hypertension Nazzareno Galiè1, Vallerie V. McLaughlin2, Lewis J. Rubin3 and Gerald Simonneau4,5 Affiliations: 1Dept of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Bologna, Italy. 2The University of Michigan, Cardiovascular Medicine, Ann Arbor, MI, USA. 3University of California, San Diego, School of Medicine, La Jolla, CA, USA. 4Univ. Paris–Sud, AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Service de Pneumologie, Département Hospitalo- Universitaire (DHU) Thorax Innovation (TORINO), Hôpital de Bicêtre, Le Kremlin Bicêtre, France. 5INSERM UMR_S999, LabEx LERMIT, Hôpital Marie Lannelongue, Le Plessis Robinson, France. Correspondence: Nazzareno Galiè, Dept of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. E-mail:
[email protected] @ERSpublications State of the art summary on diagnosis, prognosis, therapy and future perspectives of pulmonary hypertension http://ow.ly/8MHN30mGtqs Cite this article as: Galiè N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J 2019; 53: 1802148 [https://doi.org/10.1183/13993003.02148-2018]. Since 1973 the World Symposia on Pulmonary Hypertension (WSPH) proceedings have summarised the scientific advances and future needs in this field through the efforts of multiple task forces, each focusing on a different aspect of pulmonary hypertension (PH) [1]. The 6th WSPH comprised 124 experts, divided into 13 task forces, that began their work in January 2017 and presented their consensus opinions to an audience of 1376 participant attendees between February 27 and March 1, 2018 in Nice, France.